KRAS Biomarker in Lung Cancer | Hope With Answers℠

Currently, the biomarkers that have been identified for potential targeted therapy treatments for lung cancer are: EGFR, ALK, KRAS, MET, HER2, ROS1, BRAF, RET, NTRK1, PID3CA, MED1, VEGFR2, HER3, and IGF-1R. Of those, so far only EGFR, ALK+, and ROS1 have treatments approved by the FDA. However, there are many more treatments that are in clinical trials.

In this section of the Hope With Answers℠ series, learn more about the KRAS biomarker and the most current information available regarding approved treatments.

Hope With Answers Video Series: Biomarker KRAS

Discover in-depth information about the KRAS biomarker and lung cancer. Patient advocate Terri Conneran asks Dr. David Carbone from The Ohio State University James Cancer about the KRAS biomarker in lung cancer. KRAS is present in about 25% of lung cancers, but, until recently there have not been effective targeted treatments for this biomarker. Learn what new treatments are currently in trials and expected to be available for patients soon. Get the latest information on tests and treatment possibilities for this biomarker. 

Get tested for all biomarkers at once?

New study shows it's cost effective.

Next-generation sequencing can identify hundreds from a small tissue sample at once.

Living with lung cancer

She didn't think they were right

The value of a second opinion: Self-advocacy in the face of lung cancer.

Get informed.
Stay informed.

Join our community.

Sign up to get more resources on lung cancer risks, symptoms, and warning signs.